<DOC>
	<DOCNO>NCT00525733</DOCNO>
	<brief_summary>The researcher involve phase II , randomize , two-arm study , compare efficacy , safety , tolerability open-label ritonavir ( RTV ) -enhanced darunavir Truvada 5-drug multi-class regimen include truvada , darunavir/ritonavir/maraviroc/and raltegravir acutely HIV-1-infected , antiretroviral ( ARV ) drug-naïve men woman . Subjects participate least 60 week 96 week opinion investigator patient continue therapy patient 's best interest . Hypotheses : - Multi-class antiretroviral therapy ( ART ) superior RTV-enhanced ATV combination Emtricitabine/Tenofovir DF ( FTC/TDF ) respect suppression viral replication . - Multi-class ART superior RTV-enhanced ATV combination FTC/TDF respect immune reconstitution peripheral blood gastrointestinal mucosa . - Multi-class ART equivalent RTV-enhanced ATV combination FTC/TDF respect tolerability .</brief_summary>
	<brief_title>Standard Antiretroviral v. Multi-class Therapy Acutely HIV-1 Infected Antiretroviral-Naïve Subjects ( ADARC 2007-01 )</brief_title>
	<detailed_description>- DURATION : Subjects participate least 60 week 96 week opinion investigator patient continue therapy patient 's best interest . - SAMPLE SIZE : 36 subject randomize 2:1 multi-class versus standard antiretroviral therapy . - POPULATION : Acutely HIV-1-infected , antiretroviral ( ARV ) drug-naïve ( ≤ 7 day ARV treatment anytime prior study entry* ) men woman ≥ 18 year age . - REGIMEN : At entry subject randomize one follow 1:2 ratio : ARM A : FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD ARM B : FTC 200 mg/TDF 300 mg QD + darunavir 800mg/ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID The three primary objective : 1 . To assess whether multi-class regimen could completely suppress virus replication HIV infect individual base : - Plasma HIV-1 RNA level 48 week - Ultrasensitive &lt; 50 copy assay - 5 copy assay - 1 copy assay - Cell associate HIV-1RNA level week 48 - Proviral DNA - Levels week 48 - Decay rate week 12 week 48 2 . To determine whether multi-class antiviral therapy result enhance immune reconstitution peripheral blood gastrointestinal mucosa base flow immunohistochemistry . 3 . To assess tolerability multi-class compact antiviral therapy standard compact antiviral therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Acute HIV1 infection define : Negative ELISA/Western Blot indeterminate Western Blot presence HIV1 RNA &gt; 5,000 copies/ml . Positive HIV1 serology detuned ELISA O.D . value 0.5 . A documented negative serology within 180 day screen positive HIV1 serology screen Antiretroviral ( ARV ) drugnaïve ( define ≤ 7 day ARV treatment time prior entry* ) . The exception : Use antiviral part postexposure prophylaxis ( PEP ) provide subject acquire HIV1 infection event require PEP . Therapy investigational ARV drug NRTI , NNRTI , PI . Laboratory value obtain within 30 day prior study entry . Absolute neutrophil count ( ANC ) ≥ 500/mm3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 40,000/mm3 AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ≤ 7.5 × ULN Total bilirubin ≤2.5 x ULN Calculated creatinine clearance ≥60 mL/min estimate Cockcroft Gault equation : For men , ( 140 age year ) x ( body weight kg ) ÷ ( serum creatinine mg/dL x 72 ) = CrCl ( mL/min ) * For woman , multiply result 0.85 = CrCl ( mL/min ) NOTE : A program assist calculation available DMC web site : http : //www.fstrf.org/ACTG/ccc.html For woman reproductive potential , negative serum urine pregnancy test within 48 hour prior initiate study medication unless otherwise specify product labeling . Female candidate reproductive potential defined girl reach menarche woman postmenopausal least 24 consecutive month ( i.e. , menses within precede 24 month ) undergo surgical sterilization ( e.g. , hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) . Contraception requirement : Female candidate reproductive potential , participate sexual activity could lead pregnancy , must agree use least one reliable method contraception receive protocolspecified drug 6 week stop medication . Male Candidates : If heterosexual male , sexual partner must agree use acceptable method birth control entire study . Acceptable method birth control include intrauterine device ( IUD ) , diaphragm spermicide , condom sex . Oral contraceptive alone acceptablemethod birth control . Men woman age ≥ 18 year . Ability willingness subject give write informed consent . Currently breastfeed . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . NOTE : Subjects receive stable physiologic glucocorticoid dos , define prednisone ≤ 10 mg/day , exclude . Known allergy/sensitivity study drug formulation . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Serious illness require systemic treatment and/or hospitalization candidate either completes therapy clinically stable therapy , opinion site investigator , least 7 day prior study entry . NOTE : Oral candidiasis , vaginal candidiasis , mucocutaneous herpes simplex , minor illness ( judge site investigator ) restriction . Clinically relevant cardiac conduction system disease . This include severe first degree atrioventricular block ( PR interval &gt; 0.26 second ) , second , thirddegree atrioventricular block . Requirement current medication prohibit study treatment . Evidence major resistanceassociated mutation genotype perform within 14 day day 1 . Major resistanceassociated mutation include : NRTI : K65R insert Q151M , M184V/I , PI : I50L/V , I84V , N88S . Viral population either dual tropic X4 tropic use Monogram assay ( patient enter treated pending result perform within 28 day day 1 ) . Current imprisonment involuntary incarceration medical facility psychiatric physical ( e.g. , infectious disease ) illness . Participation clinical trial within 30 day prior screen . Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Acute Infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>